Drug
FB825
FB825 is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
20%
Ph phase_2
4
80%
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
4(80.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(2)
Other(1)
Detailed Status
Completed2
Recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 24 (80.0%)
Trials by Status
unknown120%
completed240%
recruiting240%
Recent Activity
2 active trials
Showing 5 of 5
recruitingphase_2
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma
NCT05008965
recruitingphase_2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT06397911
unknownphase_2
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
NCT04413942
completedphase_2
Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis
NCT05059509
completedphase_1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers
NCT02309762
Clinical Trials (5)
Showing 5 of 5 trials
NCT05008965Phase 2
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma
NCT06397911Phase 2
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT04413942Phase 2
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
NCT05059509Phase 2
Evaluate Efficacy of FB825 in Adults With Atopic Dermatitis
NCT02309762Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5